What’s hot in Boston biotech? This year, it’s the challenges that lie ahead.
That means drilling down on drug pricing, for one. On Monday, I took a look at that and some of the other insightful nuggets to come out of our event at Biogen. Today, per usual, I’ve come back with visual evidence of the festivities.
One again, a big thanks to our speakers, attendees, event host Biogen, and our supporters: platinum sponsor Ropes & Gray; gold sponsors Fairfax County Economic Development Authority and Pfizer; and silver sponsors ALT Lab Equipment, Mintz Levin, Promega, and The Richmond Group. And thanks to Keith Spiro of Keith Spiro Photography for these photos.
See you all again next year.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler
